Premium
Epigenetic inhibition by 5 Aza 2′ deoxycytidine mitigates hypertension in hyperhomocysteinemia
Author(s) -
Narayanan Nithya,
Pushpakumar Sathnur Basappa,
Qipshidze Natia,
Bratcher Adrienne P,
Tyagi Neetu,
Tyagi Suresh C
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.955.9
Subject(s) - hyperhomocysteinemia , methyltransferase , blood pressure , dna methylation , homocysteine , epigenetics , methylation , medicine , endocrinology , chemistry , gene expression , biochemistry , dna , gene
Hyperhomocysteinemia (HHcy) is a risk factor for hypertension which is associated with aortic and cardiovascular pathologies. Although the exact underlying mechanisms are still not clear, emerging evidence implicates a role of epigenetic regulation. We hypothesize that 5 Aza 2 deoxycytidine (5 Aza dC), DNMT inhibitor, lowers blood pressure by regulating methylation levels in HHCy. Wild type (WT) and CBS +/− (HHcy) mice were administered with 5 Aza dC (0.5mg/kg body weight, DNA methyl transferase (DNMT) inhibitor), for four weeks. Blood pressure measured using tail cuff and radio telemetry methods showed a significant decrease in CBS +/− mice following treatment. mRNA expression levels of DNMTs were found to be lower in CBS+/− treatment group when compared to controls. Aortic vessel reactivity was increased in myobath studies following treatment with 5 Aza dC. Ultrasound revealed an increase in abdominal and ascending aorta diameter in treated CBS +/− mice. We conclude that inhibition of DNMT, 5 Aza dC, lowers blood pressure by regulating methylation levels in HHcy and has therapeutic potential in hypertension.